• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.

作者信息

Harrington K J, Billingham L J, Brunner T B, Burnet N G, Chan C S, Hoskin P, Mackay R I, Maughan T S, Macdougall J, McKenna W G, Nutting C M, Oliver A, Plummer R, Stratford I J, Illidge T

机构信息

The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Targeted Therapy Laboratory, Section of Cell and Molecular Biology, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK.

出版信息

Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19.

DOI:10.1038/bjc.2011.240
PMID:21772330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3188925/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/f23450cbdfe6/bjc2011240f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/c2de7793a919/bjc2011240f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/3aa1bc52345a/bjc2011240f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/dcbeae8b8020/bjc2011240f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/84208c027e61/bjc2011240f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/65b138d09c99/bjc2011240f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/f23450cbdfe6/bjc2011240f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/c2de7793a919/bjc2011240f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/3aa1bc52345a/bjc2011240f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/dcbeae8b8020/bjc2011240f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/84208c027e61/bjc2011240f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/65b138d09c99/bjc2011240f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a1b/3188925/f23450cbdfe6/bjc2011240f6.jpg

相似文献

1
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.新型放射增敏剂临床前和早期临床评估指南
Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19.
2
Preclinical predictors of clinical safety: opportunities for improvement.临床安全性的临床前预测指标：改进的机会。
Clin Pharmacol Ther. 2007 Aug;82(2):210-4. doi: 10.1038/sj.clpt.6100243. Epub 2007 May 16.
3
Development of investigational radiation modifiers.研究性辐射修饰剂的开发。
J Natl Cancer Inst. 2003 May 7;95(9):646-51. doi: 10.1093/jnci/95.9.646.
4
Hypoxic cell sensitisers in radiotherapy.放射治疗中的缺氧细胞增敏剂
Lancet. 1976 Jan 24;1(7952):186-8. doi: 10.1016/s0140-6736(76)91285-x.
5
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.欧洲药品管理局关于确定和降低研究用药品首次人体试验和早期临床试验风险策略的指南评注
Br J Clin Pharmacol. 2018 Jul;84(7):1401-1409. doi: 10.1111/bcp.13550. Epub 2018 May 30.
6
Gd-Tex Pharmacyclics Inc.吉利德 - 德克斯制药公司（Gd-Tex Pharmacyclics Inc.） 需注意，“Gd-Tex”这种表述可能不太准确，也许是特定的名称缩写，若有更准确的背景信息，翻译会更精准。这里暂且按字面近似翻译。
Curr Opin Investig Drugs. 2000 Dec;1(4):524-8.
7
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.NCI-RTOG 转化研究计划放射增敏剂早期开发的战略指南。
J Natl Cancer Inst. 2013 Jan 2;105(1):11-24. doi: 10.1093/jnci/djs472. Epub 2012 Dec 10.
8
Phase 0 trials: a platform for drug development?0期试验：药物研发的一个平台？
Lancet. 2009 Jul 18;374(9685):176. doi: 10.1016/S0140-6736(09)61309-X.
9
Talaporfin: LS 11, LS11, ME 2906, mono-L-aspartyl chlorin e6, NP e6, NPE 6, taporfin sodium.
Drugs R D. 2003;4(1):69-71.
10
New designs for radiation oncology research in clinical trials.
Semin Oncol. 1981 Dec;8(4):453-72.

引用本文的文献

1
PROCR diminishes the efficacy of radiation by impairing T-cell-mediated antitumour immunity.PROCR通过损害T细胞介导的抗肿瘤免疫反应降低放疗疗效。
Nat Commun. 2025 Aug 4;16(1):7145. doi: 10.1038/s41467-025-62558-4.
2
Flavonoids attenuate inflammation of HGF and HBMSC while modulating the osteogenic differentiation based on microfluidic chip.基于微流控芯片，类黄酮通过调节成骨分化从而减轻 HGF 和 HBMSC 的炎症反应。
J Transl Med. 2024 Nov 2;22(1):992. doi: 10.1186/s12967-024-05808-1.
3
Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer.

本文引用的文献

1
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.拉帕替尼单药治疗的效果：一项在未经治疗的局部晚期头颈部鳞状细胞癌患者中进行的随机 II 期研究结果。
Br J Cancer. 2011 Aug 23;105(5):618-27. doi: 10.1038/bjc.2011.237. Epub 2011 Aug 9.
2
Characterization of image quality and image-guidance performance of a preclinical microirradiator.临床前微辐射器的图像质量和图像引导性能的特性描述。
Med Phys. 2011 Feb;38(2):845-56. doi: 10.1118/1.3533947.
3
How genetically engineered mouse tumor models provide insights into human cancers.
头颈部癌患者术前或术后联合使用AZD1775与顺铂的WISTERIA I期试验的结果及经验教训。
BJC Rep. 2024;2(1):6. doi: 10.1038/s44276-023-00026-6. Epub 2024 Jan 29.
4
Targeting the Cascade Amplification of Macrophage Colony-stimulating Factor to Alleviate the Immunosuppressive Effects Following Radiotherapy.靶向巨噬细胞集落刺激因子的级联放大以减轻放疗后的免疫抑制作用。
Research (Wash D C). 2024 Aug 20;7:0450. doi: 10.34133/research.0450. eCollection 2024.
5
Advances in the mechanism of small nucleolar RNA and its role in DNA damage response.小核仁 RNA 机制及其在 DNA 损伤反应中的作用的研究进展。
Mil Med Res. 2024 Aug 8;11(1):53. doi: 10.1186/s40779-024-00553-4.
6
Role of Exosomes in Cancer and Aptamer-Modified Exosomes as a Promising Platform for Cancer Targeted Therapy.外泌体在癌症中的作用以及适配体修饰的外泌体作为癌症靶向治疗的有前景平台
Biol Proced Online. 2024 May 27;26(1):15. doi: 10.1186/s12575-024-00245-2.
7
A review and bibliometric analysis of global research on proton radiotherapy.质子放疗的全球研究述评与文献计量分析。
Medicine (Baltimore). 2024 May 10;103(19):e38089. doi: 10.1097/MD.0000000000038089.
8
The use of master protocols for efficient trial design to evaluate radiotherapy interventions: a systematic review.使用主方案进行高效试验设计以评估放射治疗干预措施：一项系统评价。
J Natl Cancer Inst. 2024 Aug 1;116(8):1220-1229. doi: 10.1093/jnci/djae084.
9
Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization.放疗激活的 NBTXR3 纳米颗粒通过诱导溶酶体膜通透性促进铁死亡。
J Exp Clin Cancer Res. 2024 Jan 3;43(1):11. doi: 10.1186/s13046-023-02938-0.
10
Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer.调整传统药物联合免疫治疗的剂量：重塑肺癌的免疫微环境。
Front Immunol. 2023 Oct 9;14:1256740. doi: 10.3389/fimmu.2023.1256740. eCollection 2023.
基因工程小鼠肿瘤模型如何为人类癌症提供深入了解。
J Clin Oncol. 2011 Jun 1;29(16):2273-81. doi: 10.1200/JCO.2010.30.8304. Epub 2011 Jan 24.
4
Diffusion MR imaging for monitoring of treatment response.用于监测治疗反应的扩散磁共振成像。
Magn Reson Imaging Clin N Am. 2011 Feb;19(1):181-209. doi: 10.1016/j.mric.2010.10.004.
5
γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin.在外周血淋巴细胞、脾细胞、骨髓、异种移植物和皮肤中检测γ-H2AX。
Methods Mol Biol. 2011;682:249-70. doi: 10.1007/978-1-60327-409-8_18.
6
Targeted therapies in soft tissue sarcomas.软组织肉瘤的靶向治疗。
Ann Oncol. 2010 Oct;21 Suppl 7:vii277-80. doi: 10.1093/annonc/mdq288.
7
Stereotactic body radiation therapy: the report of AAPM Task Group 101.立体定向体部放射治疗：AAPM 工作组 101 报告。
Med Phys. 2010 Aug;37(8):4078-101. doi: 10.1118/1.3438081.
8
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.癌症反应标准和骨转移：RECIST 1.1、MDA 和 PERCIST。
J Cancer. 2010 Jun 28;1:80-92. doi: 10.7150/jca.1.80.
9
Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy.放射治疗中 γH2AX 和其他双链断裂生物标志物的应用。
Semin Radiat Oncol. 2010 Oct;20(4):223-31. doi: 10.1016/j.semradonc.2010.05.004.
10
DNA repair targeting and radiotherapy: a focus on the therapeutic ratio.DNA 修复靶向与放疗：关注治疗比。
Semin Radiat Oncol. 2010 Oct;20(4):217-22. doi: 10.1016/j.semradonc.2010.06.003.